The goal of the study was to examine if the treatment remained effective in minimizing NAO symptoms due to nasal valve collapse two years later, after proving successful in three-month, six-month and one-year follow ups, according to a July 13 news release from Aerin Medical.
The findings revealed that the technology was successful in improving symptoms in 90.1 percent of patients after two years, corresponding to a 57 percent improvement overall.
VivAer is a stylus that is inserted into the nostril and uses patented, temperature-controlled radiofrequency energy to alter the nasal tissue and improve airflow.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.